Digital mental health regulation is evolving as the UK MHRA launches a new industry forum to support developers with medical device compliance and patient safety.
The UK MHRA is introducing a new regulatory engagement programme for digital mental health technology developers, reflecting the growing complexity of AI-enabled healthcare and software-based medical devices.
The initiative aims to help manufacturers understand compliance expectations earlier, address regulatory knowledge gaps, and support safer innovation without weakening existing patient safety requirements.
Image
Why Does Digital Mental Health Technology Need Regulatory Attention?
Digital mental health technologies (DMHTs) are becoming an increasingly important part of healthcare.
They include smartphone applications, software platforms, AI-supported tools, and other digital products designed to support mental health assessment, monitoring, or treatment.
However, not every mental health application falls within medical device regulation. Its regulatory status depends on its intended purpose, functionality, and associated risks.
This distinction creates a difficult boundary for developers. A product marketed for general wellbeing could operate very differently from software designed to identify mental health conditions, guide clinical decisions, or support treatment.
The Medicines and Healthcare products Regulatory Agency (MHRA) recognises that these borderline products create uncertainty around medical device classification, clinical evidence, and regulatory responsibilities.
The challenge becomes greater when developers update software, refine algorithms, or introduce new functions after launch. Regulatory compliance must account for the product’s changing capabilities, not simply its original market entry.
For manufacturers, regulatory planning must become part of product development rather than a final approval exercise.
How AI Is Opening New Opportunities in Fertility Care for Pharma
"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.
Image
MHRA Introduces a Digital Mental Health Community of Practice
In an announcement published on 22 October 2026, the MHRA outlined plans to establish a Community of Practice for digital mental health technology developers and manufacturers.
The initiative will create opportunities for structured discussions between regulators and industry participants.
Its purpose is to improve understanding of common regulatory challenges and strengthen compliance capabilities across the sector.
The programme will include in-person sessions led by the MHRA and supported by an independent facilitator.
Initial discussions are expected to cover three areas:
Pre-market considerations: Understanding regulatory responsibilities before a product enters the market, including evidence requirements and development planning.
Product classification: Determining whether a digital mental health product qualifies as a medical device and identifying its appropriate risk classification.
Post-market surveillance: Understanding manufacturers’ responsibilities for monitoring product performance, identifying safety concerns, and managing emerging risks.
Importantly, the Community of Practice will not provide individual product assessments, regulatory approvals, or endorsements.
Instead, it will focus on shared industry challenges and practical regulatory understanding.
The first session is planned for 2027.
An Anonymous Survey Will Identify Industry Knowledge Gaps
The MHRA is also asking developers and manufacturers to complete an anonymous survey to help determine the programme’s priorities.
The survey assesses industry understanding across five regulatory areas:
Pre-market considerations.
Product classification.
Clinical evidence and risk management.
Vigilance.
Post-market surveillance.
The findings will help the regulator identify areas where manufacturers need greater support and shape future discussions.
The survey closes at 11:59 pm UK time on 19 November 2026.
Participation is open to digital mental health technology developers and manufacturers. Completing the survey does not automatically register participants for the Community of Practice. Respondents must separately opt in if they want information about future sessions and opportunities to participate.
The MHRA is seeking an industry-wide picture of regulatory confidence rather than simply building a mailing list.
Image
The Wider Shift Towards Lifecycle-Based AI Regulation
The initiative forms part of a wider change in the UK’s approach to healthcare technology regulation.
In September 2026, the National Commission into the Regulation of AI in Healthcare published recommendations for a future regulatory framework. The Government subsequently accepted all 44 recommendations in its response on 6 October.
The proposals support a more proportionate, risk-based, and lifecycle-focused approach to AI regulation.
The underlying principle is that regulatory oversight must account for how healthcare AI systems develop and change over time.
For digital mental health developers, this has several implications:
Evidence must remain relevant: Manufacturers need to understand whether existing clinical evidence continues to support a product as its functionality changes.
Risk management must continue after launch: Monitoring should identify emerging safety issues and changes in product performance.
Regulatory accountability must remain clear: Developers and manufacturers cannot transfer responsibility for product safety to an algorithm or external technology provider.
The MHRA’s new initiative provides a practical mechanism for exploring these challenges while the wider regulatory framework develops.
Its direction also aligns with the agency’s Strategy to 2030, which places greater emphasis on scientific capability, regulatory engagement, and supporting innovation.
For organisations developing regulated AI, these developments reinforce the importance of integrating compliance into the entire product lifecycle.
Pharmatica has also examined this issue in our Insights into regulated AI MedTech development, including the growing importance of continuous compliance and traceable development evidence.
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Image
What Should Pharmaceutical and Digital Health Leaders Do Next?
The MHRA’s announcement does not introduce new legal requirements. Existing medical device obligations remain in force.
However, the initiative gives developers an opportunity to address uncertainty before it becomes a barrier to commercialisation or patient access.
Companies developing digital mental health products should consider four priorities:
Review intended purpose and medical device classification, particularly where products combine wellbeing features with clinical functions.
Assess whether clinical evidence supports the product's intended use and target population.
Establish processes for monitoring software changes, performance, and emerging safety concerns.
Involve regulatory, clinical, quality, and product development teams early in the development process.
The opportunity actually goes beyond mental health technology. The same regulatory challenges affect AI-enabled diagnostics, clinical decision support, and other software-based medical devices.
Pharmatica’s coverage of digital health technologies in clinical development explores the wider need for evidence, governance, and regulatory alignment as digital tools become more integrated into healthcare and pharmaceutical research.
The MHRA’s Community of Practice is a constructive step towards closing the gap between technological development and regulatory understanding.
Its longer-term value will depend on whether industry engagement translates into clearer expectations, stronger compliance practices, and more consistent approaches to patient safety.
What Is the MHRA Digital Mental Health Community of Practice?
It is a new engagement programme for digital mental health technology developers and manufacturers. It will provide opportunities to discuss common regulatory challenges, including product classification, pre-market requirements, and post-market surveillance.
When Will the MHRA Community of Practice Begin?
The MHRA plans to hold its inaugural Community of Practice session in 2027. Initial topics will be informed by feedback from developers and manufacturers through an anonymous survey.
Are Digital Mental Health Applications Regulated as Medical Devices?
Some are. Their regulatory status depends on their intended purpose and functionality. Applications designed to support clinical diagnosis, treatment, or medical decision-making can fall within medical device regulation, while general wellbeing applications may not.
What Regulatory Topics Will the MHRA Survey Cover?
The survey covers five areas: Pre-market considerations, product classification, clinical evidence and risk management, vigilance, and post-market surveillance. Responses will help identify industry knowledge gaps and prioritise future discussions.
Does the New MHRA Initiative Change Existing Medical Device Regulations?
No. The Community of Practice does not introduce new legislation, replace existing requirements, or provide product approvals. Manufacturers must continue to meet applicable medical device regulations while the MHRA develops additional engagement and support mechanisms.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
2
Why not support
Nicole Dale
by giving this content a like
FDA Generic Peptides Guidance Sets New Expectations
Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.
CRO data quality decides how fast MIDD models reach regulators. See what a pharmacometric CRO survey reveals about sponsor data, costs, and AI-led fixes.
Synthetic Genetic Codes Move Closer to Programmable Biology
Synthetic genetic codes are moving closer to programmable biology as automated cell-free systems enable faster testing of new protein chemistries in R&D.
Comments (0)